FI117509B - Humanisoituja vasta-aineita leukosyyttitarttumismolekyyliä VLA-4 vastaan - Google Patents

Humanisoituja vasta-aineita leukosyyttitarttumismolekyyliä VLA-4 vastaan Download PDF

Info

Publication number
FI117509B
FI117509B FI962958A FI962958A FI117509B FI 117509 B FI117509 B FI 117509B FI 962958 A FI962958 A FI 962958A FI 962958 A FI962958 A FI 962958A FI 117509 B FI117509 B FI 117509B
Authority
FI
Finland
Prior art keywords
humanized
ser
sequence
human
gly
Prior art date
Application number
FI962958A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI962958A0 (fi
FI962958A (fi
Inventor
Jose Saldanha
Mary M Bendig
Olivier J Leger
Tarran S Jones
Ted A Yednock
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of FI962958A0 publication Critical patent/FI962958A0/fi
Publication of FI962958A publication Critical patent/FI962958A/fi
Application granted granted Critical
Publication of FI117509B publication Critical patent/FI117509B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI962958A 1994-01-25 1996-07-24 Humanisoituja vasta-aineita leukosyyttitarttumismolekyyliä VLA-4 vastaan FI117509B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18626994A 1994-01-25 1994-01-25
US18626994 1994-01-25
PCT/US1995/001219 WO1995019790A1 (en) 1994-01-25 1995-01-25 Humanized antibodies against leukocyte adhesion molecule vla-4
US9501219 1995-01-25

Publications (3)

Publication Number Publication Date
FI962958A0 FI962958A0 (fi) 1996-07-24
FI962958A FI962958A (fi) 1996-09-24
FI117509B true FI117509B (fi) 2006-11-15

Family

ID=22684288

Family Applications (1)

Application Number Title Priority Date Filing Date
FI962958A FI117509B (fi) 1994-01-25 1996-07-24 Humanisoituja vasta-aineita leukosyyttitarttumismolekyyliä VLA-4 vastaan

Country Status (21)

Country Link
EP (2) EP0804237B8 (zh)
JP (5) JP4115517B2 (zh)
KR (1) KR100367948B1 (zh)
CN (1) CN1211123C (zh)
AT (1) ATE333895T1 (zh)
AU (1) AU703152B2 (zh)
CA (1) CA2182013C (zh)
DE (2) DE69535133T2 (zh)
DK (2) DK1759709T3 (zh)
ES (2) ES2270425T3 (zh)
FI (1) FI117509B (zh)
FR (1) FR06C0024I2 (zh)
HU (1) HU220799B1 (zh)
LU (1) LU91271I2 (zh)
MX (1) MX9602971A (zh)
NL (1) NL300238I2 (zh)
NO (3) NO319867B1 (zh)
NZ (1) NZ279730A (zh)
PL (1) PL181827B1 (zh)
PT (1) PT804237E (zh)
WO (1) WO1995019790A1 (zh)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307025B1 (en) 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
NZ261259A (en) 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
AU687790B2 (en) * 1993-02-09 1998-03-05 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
AU7348798A (en) * 1997-05-09 1998-12-08 John P. Robarts Research Institute, The Method for dislodging infiltrated leukocytes from a tissue
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
ES2319831T3 (es) * 1998-09-14 2009-05-12 Board Of Regents, The University Of Texas System Metodos de tratamiento de mieloma multiple y resorcion osea inducida por mieloma usando antagonistas de la union receptor/integrina.
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
CN100360183C (zh) * 1999-04-22 2008-01-09 比奥根艾迪克Ma公司 整联蛋白α4亚单位的拮抗剂在制备治疗纤维变性的药物中的用途
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
NZ515686A (en) 1999-06-01 2005-01-28 Biogen Inc A blocking monoclonal antibody to integrin VLA-1 and its use for the treatment of inflammatory disorders such as arthritis
EP1242118B1 (en) * 1999-12-16 2009-11-11 Biogen Idec MA Inc. Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
KR100927670B1 (ko) 2001-04-13 2009-11-20 바이오겐 아이덱 엠에이 인코포레이티드 Ｖｌａ-1에 대한 항체들
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
US20040009169A1 (en) 2002-02-25 2004-01-15 Julie Taylor Administration of agents for the treatment of inflammation
AU2003226065B2 (en) * 2002-04-12 2009-02-26 Ludwig Institute For Cancer Research, Ltd Recombinant anti-interleukin-9 antibodies
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
ATE471946T1 (de) * 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
US7345049B2 (en) 2003-12-22 2008-03-18 Ajinomoto Co., Inc. Phenylalanine derivatives
CN101102792A (zh) * 2004-11-19 2008-01-09 比奥根艾迪克Ma公司 治疗多发性硬化
US20070122404A1 (en) * 2005-11-17 2007-05-31 O'keefe Theresa L Humanized immunoglobulin reactive with alpha4beta7 integrin
JP5496658B2 (ja) 2006-05-25 2014-05-21 バイオジェン・アイデック・エムエイ・インコーポレイテッド 脳卒中を処置する方法
EP2510941A3 (en) 2007-02-20 2013-01-23 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
CN101778640A (zh) * 2007-06-14 2010-07-14 比奥根艾迪克Ma公司 抗体制剂
WO2009075388A1 (ja) 2007-12-13 2009-06-18 Tokuyama Corporation フォトクロミック硬化性組成物
EP2860260A1 (en) 2008-04-11 2015-04-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
WO2010107752A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody
EP2467159A1 (en) 2009-08-20 2012-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
PL2558499T3 (pl) 2010-04-16 2017-10-31 Biogen Ma Inc Przeciwciała anty-VLA-4
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
EP2704742B1 (en) 2011-05-02 2017-07-12 Millennium Pharmaceuticals, Inc. Formulation for anti- 4 7 antibody
ES2732243T3 (es) 2012-02-16 2019-11-21 Santarus Inc Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
US20190225694A1 (en) 2016-06-28 2019-07-25 Zaklady Farmaceutyczne Polpharma Sa Recombinant production of monoclonal antibodies
US20190374639A1 (en) 2016-11-21 2019-12-12 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
EP3583126A1 (en) * 2017-02-17 2019-12-25 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
WO2018224673A1 (en) 2017-06-08 2018-12-13 Zaklady Farmaceutyczne Polpharma S.A. Improved methods of cell culture
EP3800999A4 (en) 2018-06-04 2022-06-01 Biogen MA Inc. ANTI-VLA-4 ANTIBODIES WITH REDUCED EFFECTOR FUNCTION
WO2022162164A1 (en) 2021-01-29 2022-08-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
IL95501A (en) * 1989-09-01 1997-04-15 Hutchinson Fred Cancer Res Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies
DK0625912T3 (da) * 1992-02-12 1997-10-27 Biogen Inc Behandling af inflammatorisk tarmsygdom
NZ261259A (en) * 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
AUPP647298A0 (en) 1998-10-13 1998-11-05 Keystone Retaining Wall Systems, Inc. Retaining wall block

Also Published As

Publication number Publication date
DE69535133D1 (de) 2006-09-07
HU220799B1 (hu) 2002-05-28
JP2009235078A (ja) 2009-10-15
AU1696095A (en) 1995-08-08
KR970700513A (ko) 1997-02-12
NO2017040I2 (no) 2018-08-28
MX9602971A (es) 1998-01-31
JP5487382B2 (ja) 2014-05-07
CA2182013C (en) 2007-07-17
PL315634A1 (en) 1996-11-25
FI962958A0 (fi) 1996-07-24
NO2006008I1 (no) 2006-08-07
ES2270425T3 (es) 2007-04-01
PL181827B1 (pl) 2001-09-28
NO2006008I2 (no) 2009-06-15
DE69535133T2 (de) 2008-08-21
EP1759709B1 (en) 2013-02-27
NO319867B1 (no) 2005-09-26
CN1211123C (zh) 2005-07-20
JP2006045237A (ja) 2006-02-16
WO1995019790A1 (en) 1995-07-27
CA2182013A1 (en) 1995-07-27
ES2424292T3 (es) 2013-09-30
NZ279730A (en) 1998-04-27
DK0804237T3 (da) 2006-10-16
JPH09508272A (ja) 1997-08-26
EP0804237B8 (en) 2006-11-08
FI962958A (fi) 1996-09-24
NO963097D0 (no) 1996-07-24
DK1759709T3 (da) 2013-06-10
EP0804237A1 (en) 1997-11-05
DE122006000043I1 (de) 2007-02-15
EP0804237B1 (en) 2006-07-26
NL300238I1 (zh) 2006-10-02
ATE333895T1 (de) 2006-08-15
EP0804237A4 (en) 2003-04-16
HU9602019D0 (en) 1996-09-30
JP2013173738A (ja) 2013-09-05
NL300238I2 (nl) 2007-05-01
EP1759709A1 (en) 2007-03-07
JP2013165718A (ja) 2013-08-29
FR06C0024I2 (fr) 2009-01-02
FR06C0024I1 (zh) 2006-10-13
CN1140413A (zh) 1997-01-15
HUT75129A (en) 1997-04-28
PT804237E (pt) 2006-10-31
KR100367948B1 (ko) 2003-07-12
LU91271I2 (fr) 2006-10-02
NO2017040I1 (no) 2017-08-01
AU703152B2 (en) 1999-03-18
NO963097L (no) 1996-09-24
JP4115517B2 (ja) 2008-07-09

Similar Documents

Publication Publication Date Title
FI117509B (fi) Humanisoituja vasta-aineita leukosyyttitarttumismolekyyliä VLA-4 vastaan
US5840299A (en) Humanized antibodies against leukocyte adhesion molecule VLA-4
US8246958B2 (en) Methods of inhibiting alpha-4-dependent interactions with VCAM-1 with anti-VLA-4 antibodies
US6407214B1 (en) Antibodies against E-selectin
AU747898B2 (en) Monoclonal antibodies to human CD6
CA2153692C (en) Recombinant anti-vla4 antibody molecules
CN101134779B (zh) 人cd22特异性抗体及其治疗和诊断应用
AU4032299A (en) Fap alpha-specific antibody with improved producibility
HUE029824T2 (en) New anti-GPVI antagonist antibodies, Fab fragments, and applications
US20240301047A1 (en) Methods and compositions for imaging amyloid deposits

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 117509

Country of ref document: FI

SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20060016

SPCG Supplementary protection certificate granted

Spc suppl protection certif: 300

Extension date: 20200125

MA Patent expired
SPCE Application for extension of a supplementary protection certificate [pediatric extension]

Spc suppl protection certif: L20060016

PC Transfer of assignment of patent

Owner name: BIOGEN MA INC.